Effects of Inulin-Based Prebiotics Alone or in Combination with Probiotics on Human Gut Microbiota and Markers of Immune System: A Randomized, Double-Blind, Placebo-Controlled Study in Healthy Subjects
Open accessThe DOI matches its Crossref record; 60 of the 60 references it cites were found in a registry or an index; 10 of the 68 sources its claims cite were checked for support.
Abstract
The gut microbiota is implicated in diverse interactions affecting human health. The present study reports a randomized, double-blind, placebo-controlled clinical study conducted by administering a new synbiotic formulation composed of two Lactobacillus strains (L. plantarum and L. acidophilus) and one Bifidobacterium strain (B. animalis subsp. lactis) and two types of fructans (fructo-oligosaccharides with a degree of polymerization of 3–5 and inulin-type fructans with 10 DP). The effects of this synbiotic were evaluated on healthy subjects for 28 days and the maintenance of its efficacy was evaluated at the end of a follow-up period of 28 days. The synbiotic treatment contributes to higher biodiversity of the gut microbiota, increasing the community richness with respect to the group with the prebiotics alone and the placebo group. Its positive effect is also reflected in the variation of microbial community structure favoring the beneficial short-chain fatty acids bacterial producers. The amelioration of the health status of the subjects was also established by the reduction of common infectious disease symptom incidence, the stimulation of the gut immune system showing a noteworthy variation of fecal β-defensin2 and calprotectin levels, and the modulation of the response of the respiratory tract’s immune system by salivary IgA as well as total antioxidant capacity biomarkers.
Overview
CoChat Summary
## TL;DR
This randomized, double-blind, placebo-controlled study in 75 healthy elderly subjects found that a synbiotic containing two Lactobacillus strains, one Bifidobacterium strain, and inulin/FOS improved gut microbiota diversity and several immune-related markers more than prebiotics alone or placebo. The synbiotic also reduced common infectious disease (CID) incidence and lowered fecal calprotectin while increasing fecal β-defensin2.
## Key findings
- The study enrolled 75 healthy elderly Caucasian men and women, randomized 1:1:1 to prebiotic, synbiotic, or placebo for 28 days, with 28 days of follow-up.
- Gut microbiome alpha diversity (Faith PD) increased significantly from T0 to T56 in both the synbiotic group (p = 0.045) and the prebiotic group (p = 0.02); after T0–T28, both A vs D and B vs D differed significantly (A vs D U = 149, p = 0.02; B vs D U = 301, p = 0.04).
- The synbiotic group had lower CID burden: 36% of subjects reported at least one CID episode during T0–T28 and 12% during T28–T56, versus 48%/20% in prebiotic and 56%/20% in placebo; over T0–T56, 48% of synbiotic subjects had at least one CID episode versus 68% prebiotic and 76% placebo.
- Fecal calprotectin normalized in the synbiotic group from 88% of subjects at baseline to 96% at T28 and 100% at T56; fecal β-defensin2 increased by about 22% in the synbiotic group over T0–T56, while the prebiotic group showed a 25% increase at the first endpoint and salivary TAC increased significantly only with synbiotic at T0–T28 (p < 0.05).
## Methods
- Randomized, double-blind, placebo-controlled clinical trial in 75 healthy elderly Caucasian subjects aged 60–80 years with BMI 18.5–24.99.
- Three arms: prebiotic (50 mg FOS + 50 mg inulin), synbiotic (3 probiotic strains plus the same prebiotics), and placebo, taken once daily for 28 days, with assessments at T0, T28, and T56.
- Main analyses included 16S rDNA V3–V4 sequencing, qPCR for probiotic strains, QIIME2/DADA2 community analysis, Faith PD, MAZ scoring, and nonparametric tests (Wilcoxon signed-rank, Mann-Whitney).
## Limitations
- The paper states the study had a small number of subjects because eligible elderly participants without severe concurrent diseases were difficult to enroll.
- It also states a limitation of using immune biomarkers without clinical outcomes, making minor immunomodulatory effects hard to interpret.
- Evident from the text: the population was restricted to healthy elderly Caucasian subjects, so generalizability to other ages, ethnicities, or less healthy populations is not established.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Figures














Verification
Claims the paper makes
7 Valid · 1 Not valid · 39 Not checked · 90 Own results and interpretations
Some cited sources support this claim and some don’t — read each source’s verdict below.
In the paper
“This is in line with the majority of the literature data [48,50], in which the structure of the intestinal microbial community is principally modulated by the synbiotic intake [22].”
§ Effects of Inulin-Based Prebiotics Alone or in Combination with Probiotics on Human Gut Microbiota and Markers of Immune System: A Randomized, Double-Blind, Placebo-Controlled Study in Healthy Subjects > 4. Discussion Many studies report the health-promoting properties of probiotics or synbiotic formulations composed of Lactobacillus and Bifidobacterium strains in combination with prebiotics [22,23,48,49]. However, it is known that health properties are strain-dependent and prebiotic-dependent [4,25]. Probiotics elicit their functions through different ways, including the ecological effects on gut microbial communities and immune modulation mechanisms [25]. In addition, few probiotic/prebiotic synbiotic approaches have been reported considering the positive effect under the competitive conditions of the gastrointestinal tract [22]. In this context, we considered an experimental design of a clinical study including the synbiotic treatment (B group) with respect to the group with the prebiotics alone (A group) and with respect to the placebo group (D group). The clinical study was performed evaluating the effect of the new synbiotic on both the gut microbiota and the immune system of healthy elderly subjects. To our knowledge, no other study reports the elucidation of the synbiotic effects on both healthy and elderly population, associating the microbial gut composition with the markers of health-promoting properties, and including techniques that allowed the quantification of the probiotic strains. Moreover, in literature, the experimental design rarely comprised prebiotic alone and synbiotic intake. The overall data on the biodiversity of the intestinal microbial community collected in this work indicated that the synbiotic intake led to a higher biodiversity variation after 28 days of treatment with respect to the placebo group and the biodiversity was maintained until the end of the follow-up period (T56). Interestingly, the taxa that mostly contribute to the variation of biodiversity after the synbiotic treatment (B group) are different in comparison with the prebiotic alone (A group) during the time. This is in line with the majority of the literature data [48,50], in which the structure of the intestinal microbial community is principally modulated by the synbiotic intake [22]. Many papers report that the formulation efficacy in gut microbiota modulation addressed target taxa representing beneficial bacteria, including the increase of bifidobacteria, and promoting the decrease of a limited number of opportunistic pathogens and enterobacteria [12]. Moreover, in these studies, it is reported that the significant increase of probiotic strains (as lactobacilli and bifidobacteria) is induced by the fibers [4]. In our case, we observed a slight biodiversity variation of probiotic strains (as lactobacilli and bifidobacteria) probably due to the small amount of prebiotics administered to the subjects of A and B group, although the amount of the selected prebiotics was chosen to comply with the protocol of the clinical trial development; moreover, it is clearly established that autochthonous bacterial strains could metabolize the administered prebiotics starting an antagonistic relationship against probiotics for the same fiber utilization [23]. In any case, the analysis of the whole gut microbial community provided insights on the ecological and functional impact of the synbiotic administration, through the variation of biodiversity composition. After synbiotic administration (T0–T28), Blautia, Faecalibacterium, and Ruminococcus genera had a positive cumulative variation (Figure 8) that demonstrate the efficacy of the probiotic plus the prebiotics intake against the normal decrease in the gut of elderly subjects [48]. Moreover, during the follow-up period, the synbiotic administration highlighted an increase in the variation of specific features including Bifidobacterium and Prevotella that are associated with probiotic effect and fiber intake, respectively [4,51]. A similar change of bacteria profile in the gut microbiota in the elderly subjects after the synbiotic consumption was observed by Gao et al. and Costabile et al. [48,52]. These bacteria are considered beneficial gut microorganisms and candidates for the production of short-chain fatty acids (SCFA) [53], known for their positive effects on epithelial intestinal cells [54]. Interestingly, the observed ecological gut microbiota shift could indicate an amelioration in terms of metabolic functions. Indeed, Faecalibacterium taxa possess anti-inflammatory properties as well as actively contribute to the intestinal health and the maintenance of gut homeostasis [55], as does Roseburia genus [56]. Akkermansia is also known to promote immune modulation, healthy metabolic homeostasis, and protect against inflammation [46,57]. The presence of Akkermansia is often positively correlated with a high metagenome richness and specifically with Ruminococcus and Bifidobacterium taxa [58]. Additionally, Faecalibacterium, Roseburia, and Ruminococcus are considered as butyrate producing genera [4,22], Blautia and some species of Akkermansia are known as candidates for the SCFA production [53], whereas Prevotella genus is acknowledged as long-chain fatty acids producer [59]. Probiotic strains up-regulate the release of defensin molecules by the gut epithelium and favor the decrease of the fecal calprotectin of subjects with IBS or with visceral hypersensitivity [31,60]. As a primary outcome of our study, we analysed calprotectin and β-defensin2 as fecal biomarkers to follow inflammation in the gastrointestinal tract. Calprotectin is a calcium binding protein found principally in neutrophils and released in faeces upon accumulation and activation at the site of inflammation. It is also known that fecal calprotectin levels can change with age. Indeed, few healthy subjects of the study, especially belonging to B group, showed high level of calprotectin. Thus, the possible positive effect of the synbiotic treatment was slightly detectable. However, at the end of the study period (T56), all the subjects (100%) administered with the synbiotic exhibited normal calprotectin levels. On the contrary, in the presence of gut dysbiosis and disorders (IBS, Chrohn’s diseases, etc.), the levels of calprotectin usually are high and several times higher than the values of the healthy elderly at the end of our study [29]. Likewise, the increase of human β-defensin2 secretion was observed in healthy adult volunteers after administration of lactobacilli strains [61,62]. In these papers, the authors report that only a few strains favour the effect of the β-defensins, and they suppose that the difference among the strains is in the ability to induce the defensin expression correlated with the presence of genes encoding glycosylated cell surface structures. Our data confirmed literature data [31,48], suggesting a correlation between the effects on the microbiota of the subjects of B group and the immunological tested biomarkers with respect to the placebo group. In fact, we obtained an increase in the levels of the β-defensin2 and a reduction of the fecal calprotectin during the synbiotic treatment, associated with an increase in healthy microbiota in terms of diversity, stability, and resilience. Moreover, the positive stimulation of the innate gut immune system by the synbiotic treatment, for example, observed with β-defensin2 increase, can be associated with the intestinal cell reaction and the increase of beneficial molecule production by specific bacterial genera such as Akkermansia, Prevotella, and Bifidobacterium. This is further supported by literature, in fact, Akkermansia can exhibit potential anti-inflammatory responses and potentially modulates resident gut microbiota and together with Bifidobacterium are health-associated genera well-known for promoting immune modulation and protection against inflammation [57,58]. Because it is known that respiratory infections are dominant causes of diseases or mortality in the elderly for the association of aging and decline of the innate and adaptive immune system, we analyzed also salivary IgA and salivary total antioxidant capacity (TAC) for the respiratory tract. IgAs are important actors in the intestinal microbiota homeostasis preservation and in the defence against pathogens of gastrointestinal and respiratory tracts [15]. In our study, no significant responses deriving from the IgA markers were detected, except a slight increase after the synbiotic intake, as was also observed by Kotani et al. [13]. However, when the systemic inflammatory disorders increased for a different CID susceptibility in the subjects, the CID incidence was reduced after the treatment with the synbiotic formulate, similarly to the results Lefevre et al. [28], in which they observed a reduction of CID incidence in the elderly due to probiotic intake. Concerning the ability to counteract oxidative stress, such as the imbalance between ROS production and the defence of the organism, the TAC biomarker was monitored, suggesting a positive effect after the administration of the synbiotic formulation (B group) for the period of treatment. Indeed, this salivary homeostasis occurs as a result of aging that can be counterbalanced using prebiotic plus probiotic supplements [16]. In conclusion, our study strengthened literature data regarding the effects of a new synbiotic formulation on the gut microbiota biodiversity associated with biological markers of immune system (especially correlated to β-defensin2) with respect to the placebo treatment leading to an amelioration of the decline in the health status of the elderly. Indeed, to date, no literature data reporting specific immune parameters in elderly subjects are available. In fact, the most report only observational outcomes.
What the sources say
- Partly supportedcites [48] Costabile, 2017, Effects of Soluble Corn Fiber Alone or in Synbiotic Combination with Lactobacillus rhamnosus GG and the Pilus-Deficient Derivative GG-PB12 on Fecal Microbiota, Metabolism, and Markers of Immune Function: A Randomized, Double-Blind, Placebo-Controlled, Crossover Study in Healthy Elderly (Saimes Study), Front. Immunol. sourceExperimental — accuracy not yet measured
The Results ("Blood Lipids, Glucose, Cytokines, NK Cell Activity, Phenotype, and Intestinal Microbiota Composition") do show that the synbiotics (L. rhamnosus GG + SCF and GG-PB12 + SCF) produced the strongest shift in overall fecal microbiota composition, and the Discussion reports genus-level changes (Parabacteroides up, Oscillospira and Desulfovibrio down) under synbiotic treatment — so the direction of the paraphrase is grounded. But the paper does not support 'principally': SCF (prebiotic fiber) alone also had a significant effect on overall composition, each active treatment explaining only ~2% of the variation, and Ruminococcaceae Incertae sedis rose more with SCF alone; the Introduction/Discussion frame the microbial community as host-specific and shaped by ageing and appropriate dietary intervention generally, not by synbiotic intake as the principal driver. Additionally, these findings come from a 4-week crossover trial in healthy elderly (and, for some genus effects, specific strains), a narrower population and condition than the general statement implies. (LLM, conf=0.72)
- Partly supportedcites [50] Lai, 2014, Impact of the gut microbiota, prebiotics, and probiotics on human health and disease, Biomed. J. sourceExperimental — accuracy not yet measured
Our copy supports only the general idea that dietary/pre- and probiotic intake shapes the microbial community: 'Diet composition influences the composition of the gut microbiota' (Nutrient metabolism by the intestinal microbiota) and 'Prebiotics stimulate the growth or activities of specific microbial genera and species in the gut microbiota' / 'the gut microbiota could be manipulated using diet, prebiotics, and probiotics' (Probiotics; Fecal transplantation). However, the word 'synbiotic' never appears in our copy, and the paper does not rank any intake as the principal modulator — the Human gut microbiota and host homeostasis section lists pH, peristalsis, transit time, nutrient availability, host age and health status, and mucin secretion as determinants of bacterial number and diversity. The 'principally modulated by synbiotic intake' element of the claim is therefore not attributable to this source. (LLM, conf=0.75)
- Disputedcites [22] Krumbeck, 2018, Probiotic Bifidobacterium strains and galactooligosaccharides improve intestinal barrier function in obese adults but show no synergism when used together as synbiotics, Microbiome sourceExperimental — accuracy not yet measured
Our copy states the opposite of the claim at the community level: in Results > 'Characterization of the fecal microbiota by 16S rRNA gene sequencing' the authors report that 'the treatments did not exert a community-wide effect on the resident gut microbial community' — alpha- and beta-diversity showed no differences within or across the six groups (P > 0.05). The Discussion likewise describes the effect of the synbiotic/probiotic treatments as 'remarkably specific, increasing mainly total bifidobacteria and the specific OTUs that represent the probiotic strains,' and the paper's title and Conclusion emphasize 'no synergism when used together as synbiotics.' Thus the cited work does not support the assertion that community structure is principally modulated by synbiotic intake; it reports limited, taxon-specific shifts and no community-wide modulation. (LLM, conf=0.82)
Checked by a reasoning model — may be wrong.
boostedstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Among these, Akkermansia, Bifidobacterium, Blautia, Faecalibacterium, Prevotella, Roseburia, and Ruminococcus ASVs were considered for their high rate of variation and for their relevance in inducing gut metabolism changes [46] (Figure 7).”
§ Effects of Inulin-Based Prebiotics Alone or in Combination with Probiotics on Human Gut Microbiota and Markers of Immune System: A Randomized, Double-Blind, Placebo-Controlled Study in Healthy Subjects > 3. Results > 3.4. Effects of the Synbiotic Intake on the Most Relevant Taxa
What the sources say
- Partly supportedcites [46] 2017, Emerging Trends in “Smart Probiotics”: Functional Consideration for the Development of Novel Health and Industrial Applications, Front. Microbiol. sourceExperimental — accuracy not yet measured
Our copy of El Hage et al. (2017) supports the metabolic relevance of only part of the genus list: the 'Next Generation Probiotics > Akkermansia muciniphila' section ties A. muciniphila to lipid metabolism, blood glucose, insulin resistance, plasma triglycerides and body fat distribution, and Bifidobacterium appears as a prebiotic-stimulated genus (Introduction) and in metabolic contexts in the cited work (References 15, 90), while Faecalibacterium is treated chiefly for anti-inflammatory action ('Faecalibacterium prausnitzii' section) with butyrate/SCFA production ascribed to bifidobacteria and butyrate-producing clostridia generally (Introduction). Blautia, Roseburia and Ruminococcus occur in our copy only as entries in Table 1 (strains composing the RePOOPulate consortium, 'Alternatives for Fecal Microbiota Transplant'), with no statement that they induce gut metabolism changes. Prevotella is not mentioned anywhere in our copy (searched: Prevotella; Blautia Roseburia Ruminococcus butyrate metabolism), so the seven-genus claim as a whole overreachs what this review attributes to these taxa. (LLM, conf=0.78)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“On the contrary, in the presence of gut dysbiosis and disorders (IBS, Chrohn’s diseases, etc.), the levels of calprotectin usually are high and several times higher than the values of the healthy elderly at the end of our study [29].”
§ Effects of Inulin-Based Prebiotics Alone or in Combination with Probiotics on Human Gut Microbiota and Markers of Immune System: A Randomized, Double-Blind, Placebo-Controlled Study in Healthy Subjects > 4. Discussion Many studies report the health-promoting properties of probiotics or synbiotic formulations composed of Lactobacillus and Bifidobacterium strains in combination with prebiotics [22,23,48,49]. However, it is known that health properties are strain-dependent and prebiotic-dependent [4,25]. Probiotics elicit their functions through different ways, including the ecological effects on gut microbial communities and immune modulation mechanisms [25]. In addition, few probiotic/prebiotic synbiotic approaches have been reported considering the positive effect under the competitive conditions of the gastrointestinal tract [22]. In this context, we considered an experimental design of a clinical study including the synbiotic treatment (B group) with respect to the group with the prebiotics alone (A group) and with respect to the placebo group (D group). The clinical study was performed evaluating the effect of the new synbiotic on both the gut microbiota and the immune system of healthy elderly subjects. To our knowledge, no other study reports the elucidation of the synbiotic effects on both healthy and elderly population, associating the microbial gut composition with the markers of health-promoting properties, and including techniques that allowed the quantification of the probiotic strains. Moreover, in literature, the experimental design rarely comprised prebiotic alone and synbiotic intake. The overall data on the biodiversity of the intestinal microbial community collected in this work indicated that the synbiotic intake led to a higher biodiversity variation after 28 days of treatment with respect to the placebo group and the biodiversity was maintained until the end of the follow-up period (T56). Interestingly, the taxa that mostly contribute to the variation of biodiversity after the synbiotic treatment (B group) are different in comparison with the prebiotic alone (A group) during the time. This is in line with the majority of the literature data [48,50], in which the structure of the intestinal microbial community is principally modulated by the synbiotic intake [22]. Many papers report that the formulation efficacy in gut microbiota modulation addressed target taxa representing beneficial bacteria, including the increase of bifidobacteria, and promoting the decrease of a limited number of opportunistic pathogens and enterobacteria [12]. Moreover, in these studies, it is reported that the significant increase of probiotic strains (as lactobacilli and bifidobacteria) is induced by the fibers [4]. In our case, we observed a slight biodiversity variation of probiotic strains (as lactobacilli and bifidobacteria) probably due to the small amount of prebiotics administered to the subjects of A and B group, although the amount of the selected prebiotics was chosen to comply with the protocol of the clinical trial development; moreover, it is clearly established that autochthonous bacterial strains could metabolize the administered prebiotics starting an antagonistic relationship against probiotics for the same fiber utilization [23]. In any case, the analysis of the whole gut microbial community provided insights on the ecological and functional impact of the synbiotic administration, through the variation of biodiversity composition. After synbiotic administration (T0–T28), Blautia, Faecalibacterium, and Ruminococcus genera had a positive cumulative variation (Figure 8) that demonstrate the efficacy of the probiotic plus the prebiotics intake against the normal decrease in the gut of elderly subjects [48]. Moreover, during the follow-up period, the synbiotic administration highlighted an increase in the variation of specific features including Bifidobacterium and Prevotella that are associated with probiotic effect and fiber intake, respectively [4,51]. A similar change of bacteria profile in the gut microbiota in the elderly subjects after the synbiotic consumption was observed by Gao et al. and Costabile et al. [48,52]. These bacteria are considered beneficial gut microorganisms and candidates for the production of short-chain fatty acids (SCFA) [53], known for their positive effects on epithelial intestinal cells [54]. Interestingly, the observed ecological gut microbiota shift could indicate an amelioration in terms of metabolic functions. Indeed, Faecalibacterium taxa possess anti-inflammatory properties as well as actively contribute to the intestinal health and the maintenance of gut homeostasis [55], as does Roseburia genus [56]. Akkermansia is also known to promote immune modulation, healthy metabolic homeostasis, and protect against inflammation [46,57]. The presence of Akkermansia is often positively correlated with a high metagenome richness and specifically with Ruminococcus and Bifidobacterium taxa [58]. Additionally, Faecalibacterium, Roseburia, and Ruminococcus are considered as butyrate producing genera [4,22], Blautia and some species of Akkermansia are known as candidates for the SCFA production [53], whereas Prevotella genus is acknowledged as long-chain fatty acids producer [59]. Probiotic strains up-regulate the release of defensin molecules by the gut epithelium and favor the decrease of the fecal calprotectin of subjects with IBS or with visceral hypersensitivity [31,60]. As a primary outcome of our study, we analysed calprotectin and β-defensin2 as fecal biomarkers to follow inflammation in the gastrointestinal tract. Calprotectin is a calcium binding protein found principally in neutrophils and released in faeces upon accumulation and activation at the site of inflammation. It is also known that fecal calprotectin levels can change with age. Indeed, few healthy subjects of the study, especially belonging to B group, showed high level of calprotectin. Thus, the possible positive effect of the synbiotic treatment was slightly detectable. However, at the end of the study period (T56), all the subjects (100%) administered with the synbiotic exhibited normal calprotectin levels. On the contrary, in the presence of gut dysbiosis and disorders (IBS, Chrohn’s diseases, etc.), the levels of calprotectin usually are high and several times higher than the values of the healthy elderly at the end of our study [29]. Likewise, the increase of human β-defensin2 secretion was observed in healthy adult volunteers after administration of lactobacilli strains [61,62]. In these papers, the authors report that only a few strains favour the effect of the β-defensins, and they suppose that the difference among the strains is in the ability to induce the defensin expression correlated with the presence of genes encoding glycosylated cell surface structures. Our data confirmed literature data [31,48], suggesting a correlation between the effects on the microbiota of the subjects of B group and the immunological tested biomarkers with respect to the placebo group. In fact, we obtained an increase in the levels of the β-defensin2 and a reduction of the fecal calprotectin during the synbiotic treatment, associated with an increase in healthy microbiota in terms of diversity, stability, and resilience. Moreover, the positive stimulation of the innate gut immune system by the synbiotic treatment, for example, observed with β-defensin2 increase, can be associated with the intestinal cell reaction and the increase of beneficial molecule production by specific bacterial genera such as Akkermansia, Prevotella, and Bifidobacterium. This is further supported by literature, in fact, Akkermansia can exhibit potential anti-inflammatory responses and potentially modulates resident gut microbiota and together with Bifidobacterium are health-associated genera well-known for promoting immune modulation and protection against inflammation [57,58]. Because it is known that respiratory infections are dominant causes of diseases or mortality in the elderly for the association of aging and decline of the innate and adaptive immune system, we analyzed also salivary IgA and salivary total antioxidant capacity (TAC) for the respiratory tract. IgAs are important actors in the intestinal microbiota homeostasis preservation and in the defence against pathogens of gastrointestinal and respiratory tracts [15]. In our study, no significant responses deriving from the IgA markers were detected, except a slight increase after the synbiotic intake, as was also observed by Kotani et al. [13]. However, when the systemic inflammatory disorders increased for a different CID susceptibility in the subjects, the CID incidence was reduced after the treatment with the synbiotic formulate, similarly to the results Lefevre et al. [28], in which they observed a reduction of CID incidence in the elderly due to probiotic intake. Concerning the ability to counteract oxidative stress, such as the imbalance between ROS production and the defence of the organism, the TAC biomarker was monitored, suggesting a positive effect after the administration of the synbiotic formulation (B group) for the period of treatment. Indeed, this salivary homeostasis occurs as a result of aging that can be counterbalanced using prebiotic plus probiotic supplements [16]. In conclusion, our study strengthened literature data regarding the effects of a new synbiotic formulation on the gut microbiota biodiversity associated with biological markers of immune system (especially correlated to β-defensin2) with respect to the placebo treatment leading to an amelioration of the decline in the health status of the elderly. Indeed, to date, no literature data reporting specific immune parameters in elderly subjects are available. In fact, the most report only observational outcomes.
What the sources say
- Partly supportedcites [29] Klingberg, 2019, A distinct gut microbiota composition in patients with ankylosing spondylitis is associated with increased levels of fecal calprotectin, Arthritis Res. Ther. sourceExperimental — accuracy not yet measured
Our copy supports only the dysbiosis half of the sentence: in Results > 'Dysbiosis Index score in patients with AS, patients with UC, and healthy controls', AS patients with the most pronounced dysbiosis (DI = 5) had significantly higher fecal calprotectin than those with DI < 5 (170 (58–360) vs. 58 (27–120) mg/kg; p < 0.001), with DI positively correlated with Fcal (rS = 0.303). The IBS and Crohn's disease part is not supported: IBS appears only in Methods > 'Analysis of fecal microbiota' as part of the GA-map probe design (probes distinguish HC, IBS and IBD), no calprotectin values are reported for IBS or CD patients, and the Discussion states 'The study also lacked a control group with CD.' The magnitude/comparator 'several times higher than the values of the healthy elderly' is also unattributable here — this paper's healthy controls were young (median age 22 years, Abstract > Results), not elderly, and no such fold-difference versus elderly values is reported. (LLM, conf=0.78)
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“moreover, it is clearly established that autochthonous bacterial strains could metabolize the administered prebiotics starting an antagonistic relationship against probiotics for the same fiber utilization [23].”
§ Effects of Inulin-Based Prebiotics Alone or in Combination with Probiotics on Human Gut Microbiota and Markers of Immune System: A Randomized, Double-Blind, Placebo-Controlled Study in Healthy Subjects > 4. Discussion Many studies report the health-promoting properties of probiotics or synbiotic formulations composed of Lactobacillus and Bifidobacterium strains in combination with prebiotics [22,23,48,49]. However, it is known that health properties are strain-dependent and prebiotic-dependent [4,25]. Probiotics elicit their functions through different ways, including the ecological effects on gut microbial communities and immune modulation mechanisms [25]. In addition, few probiotic/prebiotic synbiotic approaches have been reported considering the positive effect under the competitive conditions of the gastrointestinal tract [22]. In this context, we considered an experimental design of a clinical study including the synbiotic treatment (B group) with respect to the group with the prebiotics alone (A group) and with respect to the placebo group (D group). The clinical study was performed evaluating the effect of the new synbiotic on both the gut microbiota and the immune system of healthy elderly subjects. To our knowledge, no other study reports the elucidation of the synbiotic effects on both healthy and elderly population, associating the microbial gut composition with the markers of health-promoting properties, and including techniques that allowed the quantification of the probiotic strains. Moreover, in literature, the experimental design rarely comprised prebiotic alone and synbiotic intake. The overall data on the biodiversity of the intestinal microbial community collected in this work indicated that the synbiotic intake led to a higher biodiversity variation after 28 days of treatment with respect to the placebo group and the biodiversity was maintained until the end of the follow-up period (T56). Interestingly, the taxa that mostly contribute to the variation of biodiversity after the synbiotic treatment (B group) are different in comparison with the prebiotic alone (A group) during the time. This is in line with the majority of the literature data [48,50], in which the structure of the intestinal microbial community is principally modulated by the synbiotic intake [22]. Many papers report that the formulation efficacy in gut microbiota modulation addressed target taxa representing beneficial bacteria, including the increase of bifidobacteria, and promoting the decrease of a limited number of opportunistic pathogens and enterobacteria [12]. Moreover, in these studies, it is reported that the significant increase of probiotic strains (as lactobacilli and bifidobacteria) is induced by the fibers [4]. In our case, we observed a slight biodiversity variation of probiotic strains (as lactobacilli and bifidobacteria) probably due to the small amount of prebiotics administered to the subjects of A and B group, although the amount of the selected prebiotics was chosen to comply with the protocol of the clinical trial development; moreover, it is clearly established that autochthonous bacterial strains could metabolize the administered prebiotics starting an antagonistic relationship against probiotics for the same fiber utilization [23]. In any case, the analysis of the whole gut microbial community provided insights on the ecological and functional impact of the synbiotic administration, through the variation of biodiversity composition. After synbiotic administration (T0–T28), Blautia, Faecalibacterium, and Ruminococcus genera had a positive cumulative variation (Figure 8) that demonstrate the efficacy of the probiotic plus the prebiotics intake against the normal decrease in the gut of elderly subjects [48]. Moreover, during the follow-up period, the synbiotic administration highlighted an increase in the variation of specific features including Bifidobacterium and Prevotella that are associated with probiotic effect and fiber intake, respectively [4,51]. A similar change of bacteria profile in the gut microbiota in the elderly subjects after the synbiotic consumption was observed by Gao et al. and Costabile et al. [48,52]. These bacteria are considered beneficial gut microorganisms and candidates for the production of short-chain fatty acids (SCFA) [53], known for their positive effects on epithelial intestinal cells [54]. Interestingly, the observed ecological gut microbiota shift could indicate an amelioration in terms of metabolic functions. Indeed, Faecalibacterium taxa possess anti-inflammatory properties as well as actively contribute to the intestinal health and the maintenance of gut homeostasis [55], as does Roseburia genus [56]. Akkermansia is also known to promote immune modulation, healthy metabolic homeostasis, and protect against inflammation [46,57]. The presence of Akkermansia is often positively correlated with a high metagenome richness and specifically with Ruminococcus and Bifidobacterium taxa [58]. Additionally, Faecalibacterium, Roseburia, and Ruminococcus are considered as butyrate producing genera [4,22], Blautia and some species of Akkermansia are known as candidates for the SCFA production [53], whereas Prevotella genus is acknowledged as long-chain fatty acids producer [59]. Probiotic strains up-regulate the release of defensin molecules by the gut epithelium and favor the decrease of the fecal calprotectin of subjects with IBS or with visceral hypersensitivity [31,60]. As a primary outcome of our study, we analysed calprotectin and β-defensin2 as fecal biomarkers to follow inflammation in the gastrointestinal tract. Calprotectin is a calcium binding protein found principally in neutrophils and released in faeces upon accumulation and activation at the site of inflammation. It is also known that fecal calprotectin levels can change with age. Indeed, few healthy subjects of the study, especially belonging to B group, showed high level of calprotectin. Thus, the possible positive effect of the synbiotic treatment was slightly detectable. However, at the end of the study period (T56), all the subjects (100%) administered with the synbiotic exhibited normal calprotectin levels. On the contrary, in the presence of gut dysbiosis and disorders (IBS, Chrohn’s diseases, etc.), the levels of calprotectin usually are high and several times higher than the values of the healthy elderly at the end of our study [29]. Likewise, the increase of human β-defensin2 secretion was observed in healthy adult volunteers after administration of lactobacilli strains [61,62]. In these papers, the authors report that only a few strains favour the effect of the β-defensins, and they suppose that the difference among the strains is in the ability to induce the defensin expression correlated with the presence of genes encoding glycosylated cell surface structures. Our data confirmed literature data [31,48], suggesting a correlation between the effects on the microbiota of the subjects of B group and the immunological tested biomarkers with respect to the placebo group. In fact, we obtained an increase in the levels of the β-defensin2 and a reduction of the fecal calprotectin during the synbiotic treatment, associated with an increase in healthy microbiota in terms of diversity, stability, and resilience. Moreover, the positive stimulation of the innate gut immune system by the synbiotic treatment, for example, observed with β-defensin2 increase, can be associated with the intestinal cell reaction and the increase of beneficial molecule production by specific bacterial genera such as Akkermansia, Prevotella, and Bifidobacterium. This is further supported by literature, in fact, Akkermansia can exhibit potential anti-inflammatory responses and potentially modulates resident gut microbiota and together with Bifidobacterium are health-associated genera well-known for promoting immune modulation and protection against inflammation [57,58]. Because it is known that respiratory infections are dominant causes of diseases or mortality in the elderly for the association of aging and decline of the innate and adaptive immune system, we analyzed also salivary IgA and salivary total antioxidant capacity (TAC) for the respiratory tract. IgAs are important actors in the intestinal microbiota homeostasis preservation and in the defence against pathogens of gastrointestinal and respiratory tracts [15]. In our study, no significant responses deriving from the IgA markers were detected, except a slight increase after the synbiotic intake, as was also observed by Kotani et al. [13]. However, when the systemic inflammatory disorders increased for a different CID susceptibility in the subjects, the CID incidence was reduced after the treatment with the synbiotic formulate, similarly to the results Lefevre et al. [28], in which they observed a reduction of CID incidence in the elderly due to probiotic intake. Concerning the ability to counteract oxidative stress, such as the imbalance between ROS production and the defence of the organism, the TAC biomarker was monitored, suggesting a positive effect after the administration of the synbiotic formulation (B group) for the period of treatment. Indeed, this salivary homeostasis occurs as a result of aging that can be counterbalanced using prebiotic plus probiotic supplements [16]. In conclusion, our study strengthened literature data regarding the effects of a new synbiotic formulation on the gut microbiota biodiversity associated with biological markers of immune system (especially correlated to β-defensin2) with respect to the placebo treatment leading to an amelioration of the decline in the health status of the elderly. Indeed, to date, no literature data reporting specific immune parameters in elderly subjects are available. In fact, the most report only observational outcomes.
What the sources say
- Supportedcites [23] Krumbeck, 2018, Synbiotics for Improved Human Health: Recent Developments, Challenges, and Opportunities, Annu. Rev. Food Sci. Technol. source
The SYNBIOTICS IN PRACTICE section states that in vitro/in situ synbiotic screenings 'do not account for the ecological factors that will affect the probiotic strain in vivo nor how other autochthonous members of the gut microbiota may compete with the probiotic strain for the prebiotic substrate' — i.e., resident (autochthonous) taxa can ferment the administered prebiotic and compete with the probiotic for the same substrate, which is what the citing sentence paraphrases. The same review states in its own voice (RATIONALE FOR SYNERGISTIC SYNBIOTICS) that 'to become established in the GI tract, a probiotic must not only secure nutrients and other growth factors but also outcompete the resident microbiota,' and (COMMERCIAL SYNBIOTICS...) lists 'niche competition, niche partitioning, or niche exclusion with the resident microbiota' as ecological events to be assessed. The source's hedge ('may compete') matches the claim's 'could metabolize'; the added 'it is clearly established' is the citing authors' framing, not a change in content. Although the passage credits Davis et al. 2011, Sonnenburg et al. 2010 and Ventura et al. 2009, the review asserts the point in its own synthesis rather than merely reporting another's result. (LLM, conf=0.82)
boostedstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“In addition, few probiotic/prebiotic synbiotic approaches have been reported considering the positive effect under the competitive conditions of the gastrointestinal tract [22].”
§ Effects of Inulin-Based Prebiotics Alone or in Combination with Probiotics on Human Gut Microbiota and Markers of Immune System: A Randomized, Double-Blind, Placebo-Controlled Study in Healthy Subjects > 4. Discussion Many studies report the health-promoting properties of probiotics or synbiotic formulations composed of Lactobacillus and Bifidobacterium strains in combination with prebiotics [22,23,48,49]. However, it is known that health properties are strain-dependent and prebiotic-dependent [4,25]. Probiotics elicit their functions through different ways, including the ecological effects on gut microbial communities and immune modulation mechanisms [25]. In addition, few probiotic/prebiotic synbiotic approaches have been reported considering the positive effect under the competitive conditions of the gastrointestinal tract [22]. In this context, we considered an experimental design of a clinical study including the synbiotic treatment (B group) with respect to the group with the prebiotics alone (A group) and with respect to the placebo group (D group). The clinical study was performed evaluating the effect of the new synbiotic on both the gut microbiota and the immune system of healthy elderly subjects. To our knowledge, no other study reports the elucidation of the synbiotic effects on both healthy and elderly population, associating the microbial gut composition with the markers of health-promoting properties, and including techniques that allowed the quantification of the probiotic strains. Moreover, in literature, the experimental design rarely comprised prebiotic alone and synbiotic intake. The overall data on the biodiversity of the intestinal microbial community collected in this work indicated that the synbiotic intake led to a higher biodiversity variation after 28 days of treatment with respect to the placebo group and the biodiversity was maintained until the end of the follow-up period (T56). Interestingly, the taxa that mostly contribute to the variation of biodiversity after the synbiotic treatment (B group) are different in comparison with the prebiotic alone (A group) during the time. This is in line with the majority of the literature data [48,50], in which the structure of the intestinal microbial community is principally modulated by the synbiotic intake [22]. Many papers report that the formulation efficacy in gut microbiota modulation addressed target taxa representing beneficial bacteria, including the increase of bifidobacteria, and promoting the decrease of a limited number of opportunistic pathogens and enterobacteria [12]. Moreover, in these studies, it is reported that the significant increase of probiotic strains (as lactobacilli and bifidobacteria) is induced by the fibers [4]. In our case, we observed a slight biodiversity variation of probiotic strains (as lactobacilli and bifidobacteria) probably due to the small amount of prebiotics administered to the subjects of A and B group, although the amount of the selected prebiotics was chosen to comply with the protocol of the clinical trial development; moreover, it is clearly established that autochthonous bacterial strains could metabolize the administered prebiotics starting an antagonistic relationship against probiotics for the same fiber utilization [23]. In any case, the analysis of the whole gut microbial community provided insights on the ecological and functional impact of the synbiotic administration, through the variation of biodiversity composition. After synbiotic administration (T0–T28), Blautia, Faecalibacterium, and Ruminococcus genera had a positive cumulative variation (Figure 8) that demonstrate the efficacy of the probiotic plus the prebiotics intake against the normal decrease in the gut of elderly subjects [48]. Moreover, during the follow-up period, the synbiotic administration highlighted an increase in the variation of specific features including Bifidobacterium and Prevotella that are associated with probiotic effect and fiber intake, respectively [4,51]. A similar change of bacteria profile in the gut microbiota in the elderly subjects after the synbiotic consumption was observed by Gao et al. and Costabile et al. [48,52]. These bacteria are considered beneficial gut microorganisms and candidates for the production of short-chain fatty acids (SCFA) [53], known for their positive effects on epithelial intestinal cells [54]. Interestingly, the observed ecological gut microbiota shift could indicate an amelioration in terms of metabolic functions. Indeed, Faecalibacterium taxa possess anti-inflammatory properties as well as actively contribute to the intestinal health and the maintenance of gut homeostasis [55], as does Roseburia genus [56]. Akkermansia is also known to promote immune modulation, healthy metabolic homeostasis, and protect against inflammation [46,57]. The presence of Akkermansia is often positively correlated with a high metagenome richness and specifically with Ruminococcus and Bifidobacterium taxa [58]. Additionally, Faecalibacterium, Roseburia, and Ruminococcus are considered as butyrate producing genera [4,22], Blautia and some species of Akkermansia are known as candidates for the SCFA production [53], whereas Prevotella genus is acknowledged as long-chain fatty acids producer [59]. Probiotic strains up-regulate the release of defensin molecules by the gut epithelium and favor the decrease of the fecal calprotectin of subjects with IBS or with visceral hypersensitivity [31,60]. As a primary outcome of our study, we analysed calprotectin and β-defensin2 as fecal biomarkers to follow inflammation in the gastrointestinal tract. Calprotectin is a calcium binding protein found principally in neutrophils and released in faeces upon accumulation and activation at the site of inflammation. It is also known that fecal calprotectin levels can change with age. Indeed, few healthy subjects of the study, especially belonging to B group, showed high level of calprotectin. Thus, the possible positive effect of the synbiotic treatment was slightly detectable. However, at the end of the study period (T56), all the subjects (100%) administered with the synbiotic exhibited normal calprotectin levels. On the contrary, in the presence of gut dysbiosis and disorders (IBS, Chrohn’s diseases, etc.), the levels of calprotectin usually are high and several times higher than the values of the healthy elderly at the end of our study [29]. Likewise, the increase of human β-defensin2 secretion was observed in healthy adult volunteers after administration of lactobacilli strains [61,62]. In these papers, the authors report that only a few strains favour the effect of the β-defensins, and they suppose that the difference among the strains is in the ability to induce the defensin expression correlated with the presence of genes encoding glycosylated cell surface structures. Our data confirmed literature data [31,48], suggesting a correlation between the effects on the microbiota of the subjects of B group and the immunological tested biomarkers with respect to the placebo group. In fact, we obtained an increase in the levels of the β-defensin2 and a reduction of the fecal calprotectin during the synbiotic treatment, associated with an increase in healthy microbiota in terms of diversity, stability, and resilience. Moreover, the positive stimulation of the innate gut immune system by the synbiotic treatment, for example, observed with β-defensin2 increase, can be associated with the intestinal cell reaction and the increase of beneficial molecule production by specific bacterial genera such as Akkermansia, Prevotella, and Bifidobacterium. This is further supported by literature, in fact, Akkermansia can exhibit potential anti-inflammatory responses and potentially modulates resident gut microbiota and together with Bifidobacterium are health-associated genera well-known for promoting immune modulation and protection against inflammation [57,58]. Because it is known that respiratory infections are dominant causes of diseases or mortality in the elderly for the association of aging and decline of the innate and adaptive immune system, we analyzed also salivary IgA and salivary total antioxidant capacity (TAC) for the respiratory tract. IgAs are important actors in the intestinal microbiota homeostasis preservation and in the defence against pathogens of gastrointestinal and respiratory tracts [15]. In our study, no significant responses deriving from the IgA markers were detected, except a slight increase after the synbiotic intake, as was also observed by Kotani et al. [13]. However, when the systemic inflammatory disorders increased for a different CID susceptibility in the subjects, the CID incidence was reduced after the treatment with the synbiotic formulate, similarly to the results Lefevre et al. [28], in which they observed a reduction of CID incidence in the elderly due to probiotic intake. Concerning the ability to counteract oxidative stress, such as the imbalance between ROS production and the defence of the organism, the TAC biomarker was monitored, suggesting a positive effect after the administration of the synbiotic formulation (B group) for the period of treatment. Indeed, this salivary homeostasis occurs as a result of aging that can be counterbalanced using prebiotic plus probiotic supplements [16]. In conclusion, our study strengthened literature data regarding the effects of a new synbiotic formulation on the gut microbiota biodiversity associated with biological markers of immune system (especially correlated to β-defensin2) with respect to the placebo treatment leading to an amelioration of the decline in the health status of the elderly. Indeed, to date, no literature data reporting specific immune parameters in elderly subjects are available. In fact, the most report only observational outcomes.
What the sources say
- Supportedcites [22] Krumbeck, 2018, Probiotic Bifidobacterium strains and galactooligosaccharides improve intestinal barrier function in obese adults but show no synergism when used together as synbiotics, Microbiome source
The Background says few studies have systematically tested whether synbiotics improve probiotic establishment or health benefits, and that it remains unknown whether a probiotic can benefit from a prebiotic in the competitive human gut. The Discussion adds that most combinations were formulated without demonstrated synergism under gastrointestinal competition. Together, these support the citing sentence as a broad statement about the limited evidence for positive effects under those conditions. (LLM, conf=0.88)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
55 more claims
Create a free account to see all 137 claims and to verify the 58 references still open.
- Probably not a substantial claim. 43
- It may state two separate claims as one. 50
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“The estimated sample size required for Phase I of the study which compares the serum pro-inflammatory cytokines (IL-1β, IL-6 and TNF-α), the event-related potential in EEG and the fecal microbiota content between the experimental group (patients diagnosed with AUD) and the healthy control group was estimated using the G*Power 3.1.9.7 calculator for estimating sample size needed to compared between”
From Research protocol of the efficacy of probiotics for the treatment of alcohol use disorder among adult males: A comparison with placebo and acceptance and commitment therapy in a randomized controlled trial (2023) · cites this paper as [35]
Experimental — accuracy not yet measured
Citations
Cites
DADA2: High–resolution sample inference from Illumina amplicon data
Callahan, B. J., McMurdie, P. J., Rosen, M. J., Han, A. W., Johnson, A. J. A., & Holmes, S. P. (2016) · Nature Methods · doi:10.1038/nmeth.3869 · Cited by 35,698
Reproducible, interactive, scalable and extensible microbiome data science using QIIME 2
Bolyen, E., Rideout, J. R., Dillon, M. R., Bokulich, N. A., Abnet, C. C., Al-Ghalith, G. A., Alexander, H., Alm, E. J., Arumugam, M., Asnicar, F., et al. (2019) · Nature Biotechnology · doi:10.1038/s41587-019-0209-9 · Cited by 23,742 · cited 1×
“First, the raw paired-end FASTQ reads were uploaded, then a native plugin was used for the de-multiplexing step [38].”
MethodThe Ferric Reducing Ability of Plasma (FRAP) as a Measure of “Antioxidant Power”: The FRAP Assay
Benzie, I. F. F., & Strain, J. J. (1996) · Analytical Biochemistry · doi:10.1006/abio.1996.0292 · Cited by 22,951 · cited 1×
“The antioxidant potential of salivary samples was measured by Ferric Reducing Antioxidant Parameter (FRAP) assay [32].”
MethodDiet rapidly and reproducibly alters the human gut microbiome
David, L. A., Maurice, C. F., Carmody, R. N., Gootenberg, D. B., Button, J. E., Wolfe, B. E., Ling, A. V., Devlin, A. S., Varma, Y., Fischbach, M. A., et al. (2014) · Nature · doi:10.1038/nature12820 · Cited by 10,100 · cited 1×
“Indeed, Faecalibacterium taxa possess anti-inflammatory properties as well as actively contribute to the intestinal health and the maintenance of gut homeostasis [55], as does Roseburia genus [56].”
BackgroundBokulich, N. A., Kaehler, B. D., Rideout, J. R., Dillon, M., Bolyen, E., Knight, R., Huttley, G. A., & Gregory Caporaso, J. (2018) · Microbiome · doi:10.1186/s40168-018-0470-z · Cited by 5,881 · cited 2×
“To investigate if alpha diversity (Faith PD) changed significantly between the intervals of the three (successive/non-successive) different time-points, pairwise difference tests implemented in q2-longitudinal was employed [40].”
MethodEffect size, confidence interval and statistical significance: a practical guide for biologists
Nakagawa, S., & Cuthill, I. C. (2007) · Biological Reviews · doi:10.1111/j.1469-185x.2007.00027.x · Cited by 3,835
Swanson, K. S., Gibson, G. R., Hutkins, R., Reimer, R. A., Reid, G., Verbeke, K., Scott, K. P., Holscher, H. D., Azad, M. B., Delzenne, N. M., et al. (2020) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-020-0344-2 · Cited by 2,196 · cited 1×
“Third, the minimum fiber concentration suggested for a functional synbiotic [63] was used in the study, that in theory could be sufficient to stimulate the cognate gut microorganisms.”
BackgroundYou are what you eat: Diet, health and the gut microbiota
Zmora, N., Suez, J., & Elinav, E. (2019) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-018-0061-2 · Cited by 1,792 · cited 1×
“The central district of human beings is represented by the gastrointestinal tract inhabited by the microbial communities playing a fundamental role in many physiological processes, such as absorption of nutrients, protection against ingested pathogens, and the maintenance of good health [1,2] also through the communic…”
BackgroundThe Firmicutes/Bacteroidetes ratio of the human microbiota changes with age
Mariat, D., Firmesse, O., Levenez, F., Guimarăes, V., Sokol, H., Doré, J., Corthier, G., & Furet, J.-P. (2009) · BMC Microbiology · doi:10.1186/1471-2180-9-123 · Cited by 1,755 · cited 2×
“Commonly, the relative abundances of Lactobacillus and Bifidobacterium species within the intestinal microbiota are very low [4], particularly in the elderly people [11], although their beneficial properties.”
BackgroundKovatcheva-Datchary, P., Nilsson, A., Akrami, R., Lee, Y. S., De Vadder, F., Arora, T., Hallen, A., Martens, E., Björck, I., & Bäckhed, F. (2015) · Cell Metabolism · doi:10.1016/j.cmet.2015.10.001 · Cited by 1,731
Research works printed but not linked: 1
- Manfredi, E. (2015). Biological Sciences. [Ph.D. Thesis, University of Milano-Bicocca].
Cited by
Whelan, K., Alexander, M., Gaïani, C., Lunken, G., Holmes, A. J., Staudacher, H. M., Theis, S., & Marco, M. L. (2024) · Nature Microbiology · doi:10.1038/s41564-024-01831-6 · Cited by 69
“To date, there is some evidence that the therapeutic efficacy of synbiotics is greater than either probiotic or prebiotic component administered alone 43 ; however, few human studies have included a side-by-side comparison of probiotics and prebiotics consumed separately and combined 44,45 .”
Akram, W., Pandey, V., Sharma, R. K., Joshi, R., Mishra, N., Garud, N., & Haider, T. (2024) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2023.129131 · Cited by 67
Functional Foods in Clinical Trials and Future Research Directions
Hajzer, Z. E., Alibrahem, W., Helu, N. K., Oláh, C., & Prokisch, J. (2025) · Foods · doi:10.3390/foods14152675 · Cited by 52
“Baseline microbiota activity and initial bifidobacteria counts influenced responses to prebiotic dosing in healthy subjects using diet recommendations and 2, 6, or 10 g of inulin [35,36].”
Lungaro, L., Malfa, P., Manza, F., Costanzini, A., Valentini, G. M., Squarzanti, D. F., Viciani, E., Velichevskaya, A. I., Castagnetti, A., Barbalinardo, M., et al. (2024) · Nutrients · doi:10.3390/nu16234173 · Cited by 27
Asparagus Fructans as Emerging Prebiotics
Hamdi, A., Viera, I., Guillén, R., Rodríguez‐Arcos, R., Muñoz, M. J., Monje, J. M., & Jiménez‐Araujo, A. (2022) · Foods · doi:10.3390/foods12010081 · Cited by 25
Metadata
- Authors
- De Giani, A., Sandionigi, A., Zampolli, J., Michelotti, A., Tursi, F., Labra, M., & Di Gennaro, P.
- Affiliations
- Department of Biotechnology and Biosciences, University of Milano-Bicocca, Piazza Della Scienza 2, 20126 Milano, MI, Italy
- University of Milano-Bicocca (IT)
- Complife Italia S.r.l., Via Angelini 21, 27028 San Martino Siccomario, PV, Italy
- ORCID
- Venue
- Microorganisms
- Publisher
- MDPI AG
- Published
- 2022-06-20
- Volume
- 10
- Issue
- 6
- Pages
- 1256
- ISSN
- 2076-2607 (ISSN-L)
- PMC
- PMC9229734
- OpenAlex
- W4283263429
- Cited by
- 46
- References
- 60
- Citations by year
- 2026: 12 · 2025: 16 · 2024: 9 · 2023: 6 · 2022: 3
- FWCI
- 5.25
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- Microorganisms (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- BOA (University of Milano-Bicocca) (submittedVersion, cc-by)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Funders
- Natural Activities and Technologies Under Research for Healthy Aging (NATURHA) (138946)
- Topics
- Health Sciences › Nursing › Nutrition and Dietetics › Microbial Metabolites in Food Biotechnology
- Life Sciences › Agricultural and Biological Sciences › Food Science › Probiotics and Fermented Foods
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Gut microbiota and health
- Keywords
- synbiotics, inulin-type fructans, fructooligosaccharides, Lactobacillus plantarum, Lactobacillus acidophilus, Bifidobacterium animalis subsp. lactis, gut microbiota, short-chain fatty acids, human beta-defensin 2, calprotectin, salivary IgA, lung immunity, antioxidant capacity, microbial diversity, healthy volunteers
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-11, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-11 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (qwen3.8-omni-flash and gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Effects of Inulin-Based Prebiotics Alone or in Combination with Probiotics on Human Gut Microbiota and Markers of Immune System: A Randomized, Double-Blind, Placebo-Controlled Study in Healthy Subjects. https://app.cochat.ai/papers/10.3390/microorganisms10061256
- The paper
- De Giani, A., Sandionigi, A., Zampolli, J., Michelotti, A., Tursi, F., Labra, M., & Di Gennaro, P. (2022). Effects of Inulin-Based Prebiotics Alone or in Combination with Probiotics on Human Gut Microbiota and Markers of Immune System: A Randomized, Double-Blind, Placebo-Controlled Study in Healthy Subjects. Microorganisms. https://doi.org/10.3390/microorganisms10061256
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.